What changed in ten years and what is newly possible or cheap — stress urinary incontinence

1. Summary

The domain's dossier flags its own Section 7 (technology trajectory) as effectively unsearched beyond a single cross-referenced clearance count. This report fills that gap directly against FDA's own registries rather than the earlier signal-log estimate. Two things changed measurably over the last decade: the rate and geographic origin of 510(k) clearances under the incumbent electrical-stimulator product code, and the range of non-invasive modalities now cleared alongside the intravaginal probe — including chair-based magnetic stimulation and an externally-worn transcutaneous device family that did not exist under this classification before

1. What has not obviously changed is the sensing technology underneath the biofeedback

layer: a currently marketed device's own predicate comparison names a two-decades-old device as having "similar technological characteristics." A federal payment pathway for remote monitoring of therapy adherence was also created in this window, though no source found this pass ties it to a specific device in this domain.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

510(k) clearance volume: rising, and increasingly from overseas contract manufacturers

Querying FDA's 510(k) database directly for product code KPI (nonimplanted electrical continence device, 21 CFR 876.5320) over the ten-year window 2016-09-04 to 2026-09-02 returns 31 clearances; the transcutaneous product code QAJ (876.5330) returns 5 in the same window [4][5] [single-source]. Sorting the 31 KPI records by decision date: 8 were decided in the partial-plus-four years from 2016-09-04 through 2020-12-31, versus 14 decided from 2024-01-01 through 2026-09-02 (also a partial year) [4] [single-source]. Read as a raw count, not a trend claim — this is an unfiltered registry tally, the same kind of counted series docs/backlog.md 1.10 already flags as unable to carry a confidence tag on its own [inference, carried to §5]. Of the 31 KPI applicant names, at least 13 list a mainland-Chinese or Taiwanese manufacturing address in the company name itself (for example, four separate clearances from Shenzhen Konmed Technology Co., plus single clearances from Hunan Accurate Bio-Medical, Shenzhen Changkun, Dolanvy (Suzhou), Nanjing Vishee, Shenzhen Med-Link, Shenzhen Dongdixin, and two from Everyway Medical Instruments of Taiwan) [4] [single-source]. That is consistent with a device category where the underlying hardware — probe, generator, electrode pads — has become cheap enough to source through commodity contract manufacturing and clear by substantial equivalence rather than by a new clinical claim.

Two modalities that were not commercially available under these codes a decade ago

BTL Industries has cleared magnetic-field pelvic floor stimulator chairs under the KPI code across the decade (K162010 in 2016, K181497 in 2018, and K241516 in 2025); the most recent, BTL-398, is indicated for "entirely non-invasive electromagnetic stimulation of pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence" — verbatim from its own 510(k) summary [6]. A device requiring no probe insertion and no undressing below the waist, cleared under the same product code as an intravaginal electrode, is a form-factor option that did not exist for this indication in 2016.

Separately, product code QAJ's earliest record in the openFDA index queried this pass is not a 510(k) at all but a de novo classification request, DEN170049, granted 2018-11-06 for Innovo, an externally worn (non-intravaginal) electrical stimulation device [8] [single-source]. Every later QAJ clearance found — Elidah's ELITONE (K183585, 2019), a second-generation Innovo (K192357, 2020), ELITONE Urge (K223884, 2023), and Elitone for Men (K253285, 2026) — sits after that original authorization [5][8] [single-source]. A transcutaneous, non-intravaginal product line for this indication is accordingly a genuinely post-2018 development within the ten-year window, not a re-badge of an older probe design.

What has and has not changed underneath the biofeedback layer

MyOnyx (K201014, cleared 2021-01-13) pairs EMG- or pressure-based biofeedback with electrical stimulation for stress, urge, or mixed incontinence. Its own 510(k) summary names its predicate comparison directly:

"Same Biofeedback Modalities • EMG Biofeedback • Pressure Biofeedback ... CTS2000 Pelvic Floor Training System (K023906, Product Code KPI): Offers EMG and pressure biofeedback with similar technological characteristics for use in the treatment of urinary incontinence" — [7]

CTS2000 (K023906) is an early-2000s clearance under the same product code. Read narrowly: a device marketed in 2026 characterizes its own core sensing modality as technologically similar to a device roughly two decades older, per the 510(k) summary's own predicate table — the form factor, connectivity, and manufacturing origin of these devices have visibly moved in ten years; the underlying EMG/pressure sensing approach, on this one device's own account, has not.

Separate from the registry record, three small trials touch app- or coil-delivered variants of this technology without establishing an outcome advantage. A mobile app that displayed a real-time EMG-visual guide during home PFMT increased self-reported repetition adherence at 2 and 3 months versus written instructions alone (n=21, 12 vs. 9 per arm), but found no between-group difference in urinary symptom or quality-of-life scores [3] [single-source]. A 2026 randomized comparison of PFMT versus extracorporeal magnetic innervation (n=35, 19 vs. 16) found significant within-group improvement in both arms on incontinence severity, pelvic floor muscle strength, and quality of life, and "no significant between-group differences ... for these outcomes" [1] [single-source]. An uncontrolled prospective series of a 3-Tesla magnetic stimulation chair (n=100 mixed SUI/OAB) reported subjective cure or improvement in 68.3% of the 60 SUI-symptom patients at two months, self-reported and with no comparator arm [2] [single-source].

A payment pathway for remote monitoring that did not exist for most of this decade

CMS's CY2022 Physician Fee Schedule final rule contains, in its own text, a section titled "Remote Therapeutic Monitoring/Treatment Management" describing "Remote Therapeutic Monitoring (RTM)" as "a family of five codes" newly finalized for payment effective 2022-01-01, covering non-physiologic monitoring such as therapy adherence and therapy response [9]. This is a new federal payment mechanism that had no equivalent for most of the KPI/QAJ clearance history reviewed above. No source found this pass ties any named device in this domain to billing under it; that gap is recorded in Section 5.

4. Sources

[1] Comparison of Pelvic Floor Muscle Training and Extracorporeal Magnetic Innervation on Urinary Incontinence, Pelvic Floor Muscle Strength, and Quality of Life in Women With Urinary Incontinence: A Randomized Controlled Trial — Journal of Wound, Ostomy, and Continence Nursing (published 2026 Jan-Feb; accessed 2026-09-01). PMID 41540582 — https://pubmed.ncbi.nlm.nih.gov/41540582/ [peer-reviewed] [2] Efficacy of 3 Tesla Functional Magnetic Stimulation for the Treatment of Female Urinary Incontinence — Journal of Clinical Medicine (published 2022-05-16; accessed 2026-09-01). PMID 35628930 — https://pubmed.ncbi.nlm.nih.gov/35628930/ [peer-reviewed] [3] The Adherence of Home Pelvic Floor Muscles Training Using a Mobile Device Application for Women With Urinary Incontinence: A Randomized Controlled Trial — Female Pelvic Medicine & Reconstructive Surgery (published 2020 Nov; accessed 2026-09-01). PMID 30624250 — https://pubmed.ncbi.nlm.nih.gov/30624250/ [peer-reviewed] [4] FDA 510(k) clearances, product code KPI (Stimulator, Electrical, Non-Implantable, For Incontinence) — openFDA device/510k database (accessed 2026-09-01). 21 CFR 876.5320 — https://api.fda.gov/device/510k.json?search=product_code:KPI [federal-registry] [5] FDA 510(k) clearances, product code QAJ (Cutaneous Electrode Stimulator For Urinary Incontinence) — openFDA device/510k database (accessed 2026-09-01). 21 CFR 876.5330 — https://api.fda.gov/device/510k.json?search=product_code:QAJ [federal-registry] [6] 510(k) BTL-398 — FDA (decision 2025-02-10; accessed 2026-09-01). K241516 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K241516 [federal-registry] [7] 510(k) MyOnyx System — FDA (decision 2021-01-13; accessed 2026-09-01). K201014 — https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201014.pdf [federal-registry] [8] De novo classification request, Innovo, Bio-Medical Research, Ltd. — FDA (decision 2018-11-06; accessed 2026-09-01). DEN170049 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=DEN170049 [federal-registry] [9] Medicare Program; CY 2022 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies — Federal Register, 86 FR 64996 (published 2021-11-19; accessed 2026-09-01). FR Doc. 2021-23972 — https://www.federalregister.gov/documents/2021/11/19/2021-23972/medicare-program-cy-2022-payment-policies-under-the-physician-fee-schedule-and-other-changes-to-part [federal-registry]

5. Sourcing & Gaps

Well established: nothing in this report rests on two independent, non-affiliated sources — every quantitative or verbatim line here is a single registry query, a single 510(k) record, a single Federal Register document, or a single trial's own report, and is marked accordingly.

Thin: the KPI/QAJ clearance counts and their sub-period split [4][5] are a single query each and are read narrowly in §3 as a raw count, not a trend. The Chinese/Taiwanese-manufacturer count [4] is this report's own tally against the applicant-name field of the same registry query, not a separate source. All three literature findings [1][2][3] are single, small studies (n=21, n=35, n=100) — [2] is uncontrolled and self-reported, [1] is a head-to-head RCT that found no between-group difference, and [3] found an adherence difference but no symptom or quality-of-life difference between arms.

Rescoped from class 3: none in this report. Every proposition here is a registry fact, a 510(k)/de novo record, a Federal Register document, or a published trial's own reported result — none asks what a person would do.

Out of scope: CPT descriptors (the RTM code numbers and their AMA-licensed billing language), consistent with the dossier's own §6 boundary; fda.gov guidance documents; any non-US, non-EU jurisdiction (this report queried only US sources, consistent with the domain's stated US scope).

Not searched vs. not found:

• Not searched: patent filings for closed-loop EMG-gated stimulation control methods (the patent connector resolves a single known patent number rather than a topic search, and no specific number was in hand); unit cost or bill-of-materials data for any named device; any EU CE-mark equivalent of the FDA clearance trajectory above.
• Not found: a PubMed search for "closed-loop EMG biofeedback pelvic floor stimulation" (same 10-year window) returned zero records — no published study of an EMG-gated, closed-loop control algorithm specific to this indication was located, consistent with the domain dossier's own §4 finding that no such comparative trial exists. No source located this pass ties the CY2022 Remote Therapeutic Monitoring payment codes [9] to any named device in this domain's KPI or QAJ product-code set; that link is not asserted here.

[inference] The KPI clearance-count rise (8 in 2016–2020 vs. 14 in 2024–2026 YTD) and the concentration of recent applicants among overseas contract manufacturers are read together here as a commoditization pattern — hardware getting cheaper to bring to market via substantial equivalence — rather than as evidence of a clinical or functional advance. A reader could read the same 31-record list differently; the registry count itself supports only the tally, not the interpretation.

6. Claim Candidates

Propositions a checker could attempt. This report does not append them — /research drafts them onto a candidate with engine/scripts/append_research_claims.py, which constructs the unverified tag itself.